Teva and MAbxience Expand Strategic Partnership to Include an Additional Oncology Biosimilar Candidate
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Teva Pharmaceutical's US Affiliate Launches Octreotide Acetate for Injectable Suspension
Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 A.m. ET on November 6, 2024
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Amazon to Provide Opioid Overdose Drug in Workplace
100 billion US dollars in tax credits! Harris wants to "revitalize American manufacturing"
Harris stated that she will provide funding for the future 100 billion US dollar tax relief over the next ten years by increasing taxes on American companies' overseas income, including biotechnology, aviation, ai, quantum computing and other cutting-edge industries, as well as traditional industries such as iron and steel.
The "gunpowder smell" of the USA election is getting stronger! Reports of shots fired at and damage to Harris' campaign team, with no injuries.
At the same time, Trump is also focusing a lot of energy on economic policies, but some economists warn that Trump's tariffs and large-scale expulsion plan may lead to soaring prices.
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Revenues Are Not Doing Enough For Some Investors
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Barclays analyst Balaji Prasad maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
Jefferies analyst Glen Santangelo maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success
Teva Pharmaceutical's Movement Disorder Drug Shows Sustained Improvement in Extension Study
Reported Saturday, Teva Unveils Data on UZEDY Injection Switching Strategy for Schizophrenia Treatment at ECNP
Reported Saturday, Teva's New Schizophrenia Treatment TEV-749 Meets Key Endpoints in Phase 3 Study
Medincell's Partner Teva Provided Treatment Insights Into Switching to UZEDY From Perseris
Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data From Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed With Schizophrenia
Express News | Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients With Debilitating Movement Disorder Tardive Dyskinesia